Browsing Tag
primary biliary cholangitis
11 posts
Why GILD stock sentiment may depend on more than one positive Phase 3 liver disease result
Find out why GILD stock sentiment may need more than positive Livdelzi data as investors weigh Gilead’s liver disease growth strategy.
June 5, 2026
How the cholestatic liver disease market is creating new opportunities for NTCP-targeting therapies
Assembly Biosciences is expanding ABI-6250 into PBC and PSC. Find out why NTCP-targeting therapies are gaining momentum in hepatology.
May 24, 2026
Mirum Pharmaceuticals (NASDAQ: MIRM) jumps 13% after VISTAS Phase 2b PSC win
Two Phase 2b wins in seven days. A pre-NDA meeting this summer. Mirum is starting to look less like a single-product rare disease story.
May 5, 2026
GSK to sell linerixibat rights to Alfasigma for up to $690m as rare liver disease drug nears FDA approval
GSK and Alfasigma agree worldwide licence for linerixibat, a rare liver disease itch drug nearing FDA approval. Deal worth up to $690 million. Read more.
March 9, 2026
Gilead Sciences’ seladelpar gains support as PBC treatment in Europe
In a significant milestone for liver disease therapeutics, Gilead Sciences, Inc. has announced that the Committee for Medicinal…
December 15, 2024
Gilead Sciences completes $4.3bn acquisition of CymaBay Therapeutics to enhance liver disease portfolio
Gilead Sciences, Inc. (Nasdaq: GILD) has officially announced the successful acquisition of CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for…
March 23, 2024
Gilead Sciences to acquire CymaBay Therapeutics to enhance liver disease portfolio
In a significant move within the biopharmaceutical industry, Gilead Sciences, Inc. (Nasdaq: GILD) has confirmed its acquisition of…
February 14, 2024
Lupin obtains FDA approval for generic version of Ocaliva Tablets
Indian pharmaceutical company Lupin has announced its approval from the US Food and Drug Administration (FDA) for its…
June 3, 2023
Lupin bags tentative approval for Ocaliva Tablets generic in US
Lupin said that it has been issued tentative approval for Obeticholic Acid Tablets, 5 mg and 10 mg…
March 24, 2023
Cadila Healthcare gets FDA nod for phase 2(b)/3 trial of saroglitazar magnesium
Cadila Healthcare (Zydus Cadilla) said that it has obtained permission from the US Food and Drug Administration (FDA)…
December 12, 2021